Abstract

Leadership Analyzed

Human Resource Considerations

Organizational Structure of Johnson & Johnson

Factors Contributed to its Current State

Recommendations for Leadership/Structure Changes

I need help on how to compile this Analysis together based on this Case below and headings above please - Case 19 Johnson and Johnson

CASE19

JOHNSON & JOHNSON^*

On January 26, 2017, Johnson & Johnson, the world's largest health care company, bolstered its roster of treatments for rare diseases by announcing a $30 billion deal to acquire Actelion, a Swiss biotechnology firm. The deal expanded its portfolio of leading medicines and promising late stage products. "We believe this transaction offers compelling value to both Johnson & Johnson and Actelion shareholders" Alex Gorsky, the chairman and chief executive of J&J, stated in a news release.¹

With 250 companies in virtually every country, J&J has under its banner the world's largest medical device business, an even bigger pharmaceutical business, and a consumer products division with a dozen megabrands, from Neutrogena to Tylenol. Although the firm is best known for its common consumer products, its biggest recent growth has come from its vast range of pharmaceuticals. J&J has advantages from its diversified businesses such as greater financial stability, a wider range of expertise, and a customer base that spans consumers to hospitals to governments.